• Veracyte Inc VCYT.OQ reported quarterly adjusted earnings of 19 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of eleven analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from -6 cents to 9 cents per share.

• Revenue rose 28.6% to $115.86 million from a year ago; analysts expected $109.81 million.

• Veracyte Inc's reported EPS for the quarter was 19 cents​.

• The company reported quarterly net income of $15.16 million.

• Veracyte Inc shares had risen by 5.6% this quarter and gained 30.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 343.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Veracyte Inc is 40.00

This summary was machine generated from LSEG data November 7 at 04:41 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)